ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The molecular product technology provider followed a nine-figure, SoftBank-led round two years ago with a series C led by the corporate's Vision Fund.

Agilent and Lam Research participated in a $30m round for UCSF's DNA analysis spinout, Mission Bio, whose existing shareholders include Stanford-StartX Fund.

TU Dresden spinout DenovoMatrix hopes to commercialise a method for effectively cultivating stem cell production.

Vertical Venture Partners has joined university venture fund Highlander Venture Fund as an investor in UC Riverside-founded mosquito repellent developer Sensorygen.

Agilent and Lam Research participated in a $30m series B for UCSF's DNA analysis spinout Mission Bio, whose existing shareholders include Stanford-StartX Fund.

Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.

University College London hopes to generate as much as $126m for its second Technology Fund, with British Business Bank thought to be among potential limited partners.

IP Group has poured more funding into Istesso, whose treatment for rheumatoid arthritis traces its roots to an Aberdeen spinout, to drive immuno-metabolism therapies for autoimmune diseases.